《新股表現》百心安-B(02185.HK)反覆續漲逾19%屢破頂
今日(1月3日)是百心安-B(02185.HK)上市第七個交易天,股價除首掛日「潛水」曾低見18.32元獲承接,收市僅跌5.4%報20.1元外,其餘均反覆上升,今天股價平開27.05元,曾反覆回吐至26.55元拒絕再下,曾抽升至32.5元(較上市價21.25元累漲約53%)屢創新高,現報32.3元,急漲19.4%,成交增至32.6萬股,涉資1,012萬元。
百心安是內地創新介入式心血管裝置公司。股份於12月23日,以每股21.25元(招股範圍下限定價)在港上市,淨籌約4.42億元。百心安上周三(29日)收市後宣布即將於歐洲進行經橈動脈入徑治療未控高血壓及頑固性高血壓的RADIUS-HTN試 驗,公司已與歐洲心血管研究中心(CERC)訂約進行一項歐洲臨床試驗,評估公司自主研發的第二代Iberis腎神經阻斷(RDN)系統。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.